<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
SCHEDULE 14D-1
TENDER OFFER STATEMENT PURSUANT TO SECTION 14(d)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
FINAL AMENDMENT
AMGEN INC.
(Name of Subject Company)
PHARMAINVEST, L.L.C.
PHARMACEUTICAL ROYALTIES, L.L.C.
PHARMACEUTICAL ROYALTY INVESTMENTS LTD.
PHARMACEUTICAL PARTNERS, L.L.C.
(Bidders)
CONTRACTUAL CONTINGENT PAYMENT RIGHTS ARISING FROM THE PURCHASE OF
CLASS A INTERESTS
OF AMGEN CLINICAL PARTNERS, L.P.
(Title of Class of Securities)
NONE
(CUSIP Number of Class of Securities)
---------------
PABLO LEGORRETA, DAVE MADDEN
PHARMAINVEST, L.L.C.
70 E. 55th St., 23rd Floor
New York, NY 10022
(800) 600-1450
---------------
COPIES TO:
F. GEORGE DAVITT, ESQ.
TESTA, HURWITZ & THIBEAULT, LLP
HIGH STREET TOWER 125 HIGH STREET
BOSTON, MA 02110
(Name, Address and Telephone Number
of Person Authorized to Receive Notices and Communications
on Behalf of Bidder)
---------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
This Final Amendment amends and supplements the Tender Offer Statement on
Schedule 14D-1 filed by PharmaInvest, L.L.C., a Delaware limited liability
company (the "Purchaser"), on behalf of Pharmaceutical Royalties, L.L.C., a
Delaware limited liability company, and Pharmaceutical Royalty Investments
Ltd., a Bermuda company (collectively the "Funds"), and on behalf of
Pharmaceutical Partners, L.L.C., a Delaware limited liability company and the
sole member of the Purchaser, relating to the offer by Purchaser to purchase
outstanding contractual contingent payment rights arising from the purchase
of Class A Interests of Amgen Clinical Partners, L.P. (the "CCPRs") at
$240,000 per CCPR, net to the seller in cash, without interest thereon, on
the terms and subject to the conditions set forth in the Offer to Purchase,
dated August 21, 1997 (the "Offer to Purchase"), and in the related Letter of
Transmittal, and the amendment and supplement thereto, copies of which are
attached hereto as Exhibits (a)(1), (a)(2) and (a)(4), respectively (which
collectively constitute the "Offer").
The Offer expired at 12:00 Midnight (Eastern Standard time) on September
24, 1997.
At the time of expiration, 50.125 CCPRs had been tendered and not
withdrawn. On September 29, 1997, the Purchaser accepted for payment all
tendered CCPRs, payment for which will be made promptly.
2
<PAGE>
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: September 29, 1997 PHARMAINVEST, L.L.C.
By: /s/ Pablo Legorreta
-------------------------------------
Name: Pablo Legorreta
Title: Managing Member of Pharmaceutical
Partners, L.L.C., the Manager
-----------------------------------
PHARMACEUTICAL ROYALTIES, L.L.C.
By: /s/ Pablo Legorreta
--------------------------------------
Name: Pablo Legorreta
Title: Managing Member of Pharmaceutical
Partners, L.L.C., the Manager
-----------------------------------
PHARMACEUTICAL ROYALTY
INVESTMENTS LTD.
By: /s/ Pablo Legorreta
--------------------------------------
Name: Pablo Legorreta
Title: Managing Member of Pharmaceutical
Partners, L.L.C., the Manager
-----------------------------------
PHARMACEUTICAL PARTNERS, L.L.C.
By: /s/ Pablo Legurreta
-------------------------------------
Name: Pablo Legorreta
Title: Managing Member
----------------------------------
3
